A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 186 800 KRW -1.99% Market Closed
Market Cap: 10.3T KRW

ABL Bio Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ABL Bio Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Net Income (Common)
-â‚©20.5B
CAGR 3-Years
22%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Net Income (Common)
â‚©492.1B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
22%
SK Bioscience Co Ltd
KRX:302440
Net Income (Common)
-â‚©53.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Net Income (Common)
-â‚©32.6B
CAGR 3-Years
-29%
CAGR 5-Years
8%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Net Income (Common)
â‚©127B
CAGR 3-Years
44%
CAGR 5-Years
41%
CAGR 10-Years
28%
Alteogen Inc
KOSDAQ:196170
Net Income (Common)
â‚©94.3B
CAGR 3-Years
249%
CAGR 5-Years
60%
CAGR 10-Years
77%
No Stocks Found

ABL Bio Inc
Glance View

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
15 915.23 KRW
Overvaluation 91%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Net Income (Common)?
Net Income (Common)
-20.5B KRW

Based on the financial report for Jun 30, 2025, ABL Bio Inc's Net Income (Common) amounts to -20.5B KRW.

What is ABL Bio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
7%

Over the last year, the Net Income (Common) growth was 43%. The average annual Net Income (Common) growth rates for ABL Bio Inc have been 22% over the past three years , 7% over the past five years .

Back to Top